-
1
Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a poor prognosis for advanced stages, highlighting the need for better therapeutic targets.
-
2
Deubiquitinating enzymes (DUBs) are crucial in CRC, influencing pathways related to tumor proliferation, immune evasion, and treatment resistance.
-
3
DUBs are classified into seven families and collectively impact key biological processes that drive CRC progression and therapeutic outcomes.
-
4
The article emphasizes a functional convergence framework for DUBs, suggesting they regulate multiple pathways rather than acting independently.
-
5
Innovative DUB-targeting strategies, including PROTACs and DUBTACs, aim to overcome drug resistance and enhance precision therapy in CRC.
